Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms

Autor(es)

Scopim-Ribeiro, Renata ^{[1, 2]} ; Machado-Neto, Joao Agostinho ^{[1, 2]} ; Campos, Paula de Melo ^[2] ; Niemann, Fernanda Soares ^[2] ; Lorand-Metze, Irene ^[2] ; Costa, Fernando Ferreira ^[2] ; Olalla Saad, Sara Teresinha ^[2] ; Traina, Fabiola ^{[1, 2]}

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Sch Med, Dept Internal Med, BR-14049 Ribeirao Preto, SP - Brazil

^[2] Univ Estadual Campinas, Hemoctr Unicamp, Inst Nacl Ciencia & Tecnol Sangue, Hematol & Hemotherapy Ctr, Rua Carlos Chagas 480, BR-13083878 Campinas, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: DIAGNOSTIC PATHOLOGY; v. 11, MAR 16 2016.
• Citações Web of Science: 4

Resumo

Background: New sequencing technologies have enabled the identification of mutations in Ten-eleven-translocation 2 (TET2), an enzyme that catalyzes the conversion of 5-methylcytosine into 5-hydroxymethylcytosine (5-hmC) in myeloid neoplasms. We have recently identified reduced TET2 mRNA expression in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), which is associated with a poor overall survival in MDS. We herein aimed to investigate TET2 mutations and their impact on TET2 expression in a cohort of patients with myeloid neoplasms, including MDS and AML patients. Findings: TET2 mutations were observed in 8 out of 19 patients (42 %) with myeloid neoplasms. The TET2 expression profile was similar between in wild type and in TET2 mutated patients. Conclusion: Our results suggest that TET2 expression is reduced in MDS/AML patients, independently of mutational status. (AU)

• Processo FAPESP: 12/09982-8 - Investigação de alterações moleculares em neoplasias mielóides
• Beneficiário: Fabíola Traina
• Linha de fomento: Auxílio à Pesquisa - Regular
• Processo FAPESP: 11/15905-3 - Estudo de mutações, expressão e função de Dnmt3a em síndromes mielodisplasias e leucemias mielóides agudas
• Beneficiário: Renata Scopim Ribeiro
• Linha de fomento: Bolsas no Brasil - Mestrado
• Processo FAPESP: 11/51959-0 - Biologia das doenças neoplásicas da medula óssea
• Beneficiário: Sara Teresinha Olalla Saad
• Linha de fomento: Auxílio à Pesquisa - Temático